Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study

This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the EBMT aute leukemia working group (ALWP) registry. We identified 154 patients with sAML who underwent haploHCT from 2006‐2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty‐seven (38.0%) patients underwent MAC conditioning and 97 (62.0%) RIC conditioning. Multivariate analysis showed that there was no difference in RI, NRM, LFS, OS, or GRFS for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T‐cell depletion with ATG resulted in higher NRM and inferior LFS, OS, and GRFS compared to post‐transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with p values <0.05). Our data shows that haploHCT is a feasible alternative for sAML when matched transplantation is unavailable. This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - March 14, 2018 Category: Hematology Authors: Zhuoyan Li, Myriam Labopin, Fabio Ciceri, Didier Blaise, Johanna Tischer, Gerhard Ehninger, MT Van Lint, Yener Koc, Stella Santarone, Edouard Forcade, Luca Castagna, Emmanuelle Polge, Audrey Mailhol, Annalisa Ruggeri, Mohamad Mohty, Bipin N Savani, Arnon Tags: Research Article Source Type: research